Onconova Therapeutics Profit Margin

The latest profit margin for ONTX is 321546.12% as of March 2026. That compares with -8797.22% in the prior-year period — up 3755.1% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside Onconova Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ONTX's profit margin moved from -8797.22% to 321546.12% — a 3755.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Onconova Therapeutics's valuation or profitability profile.

Against Healthcare companies, ONTX currently prints 321546.12% for profit margin, while the sector average sits near 13.89%. That is roughly 2314334.5% above the sector mean. Large gaps often invite a closer look at Onconova Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Onconova Therapeutics converts resources into returns. At 321546.12%, ONTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -8797.22% in the prior-year period — up 3755.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ONTX's profit margin (321546.12%), review year-over-year change from -8797.22%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.